![]() Three of these 5 products represented over $0.3 billion in full-year 2020 revenue for Merck: Renglexis, $135 million Brenzys, $74 million and Ontruzant, $115 million. Merck is also handing its trastuzumab (Ontruzant) biosimilar franchise over to Organon. Organon will sell these biosimilars in partnership with Samsung Bioepis of Republic of Korea. Organon will also market the etanercept biosimilar Brenzys, which the company says is the market share leader in Canada. Hadlima is scheduled to launch in the United States in 2023. Officials of the new Organon enterprise said they are counting on sales growth from the following biosimilars: Renflexis (infliximab) in the United States, Aybintio (bevacizumab) in the European Union, and Hadlima (adalimumab) in Canada and Australia. Organon, the planned Merck biosimilars and women’s health products spinoff slated to go public in June 2021, was featured in a presentation. Organon Officials Introduce Their Biosimilars Strategy Although Chinese government reforms have improved the market for biologics producers, it remains challenging for foreign producers. The factory was built, but Pfizer said in March it had made a difficult decision to discontinue production activity in China and sell the installation to WuXi Biologics, a China-based company. In 2016 it began an ambitious $350 project to build a biosimilars manufacturing center in Huangzhou. The company said biosimilar revenues climbed 79% to $530 million, led by recent launches of rituximab (Ruxience), bevacizumab (Zirabev), and trastuzumab (Trazimera) biosimilars, as well as growth from the more established epoetin biosimilar Retacrit.ĭuring the first quarter, Pfizer announced it was withdrawing from biosimilars production within the China market. Without the vaccine revenue, Pfizer’s sales increased 8%. Net income was $4.9 billion, also a 45% improvement. Pfizer reported first quarter 2021 revenues of $14.6 billion, up 45% from the comparable year-ago quarter, and stated that increased biosimilar revenues partly helped fuel this growth, although the bulk of the revenue increase stemmed from $3.5 billion in sales of Pfizer’s COVID-19 vaccine, BNT162b2. “Specifically, there are 3 key areas where we would like to see Congress and the administration focus: rebate reform, capping beneficiary cost-sharing in Medicare Part D, and incentivizing the uptake of biosimilars.” On the national level, Pfizer is working with the Biden administration and lawmakers to improve patient access also, Bourla said. ![]() We have also worked with state policymakers to advance legislation in several states ensuring that patient assistance provided by manufacturers will count toward the patient’s deductible and out-of-pocket maximums,” Bourla said. This includes legislation to require that 100% of negotiated rebates be passed through to consumers at the pharmacy counter. “At the state level, we have focused our efforts on meaningful solutions to directly address patient affordability challenges. In remarks issued with 2021 first quarter earnings statement, Pfizer Chairman and CEO Albert Bourla said the company continues to work with legislators to ensure that manufacturer rebates are passed along to patients in the form of savings, rather than going into the pockets of payers and PBMs.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |